Volition Signs First Commercial Project Utilizing Rapid High-Throughput Model in the Study of NETosis
VolitionRx (NYSE AMERICAN: VNRX) has announced its first commercial sale of their High Throughput Synthetic Sepsis method, a breakthrough technology that measures Neutrophil Extracellular Traps (NETs) activation and inhibition in whole blood in real time. This innovative approach helps companies develop new therapeutics for sepsis and NETs-related diseases.
The technology addresses significant limitations in previous research by measuring NETs directly in whole blood, avoiding potential alterations in neutrophil responses caused by isolation procedures. The method provides a more physiologically relevant environment for studying neutrophil responses and enables precise measurement of NETs formation.
Sepsis, responsible for approximately 370,000 US deaths annually, involves NETs which are essential for trapping and neutralizing pathogens. However, their overproduction can lead to tissue damage and disease progression. This new technology aims to enhance understanding of conditions characterized by uncontrolled NETs formation and serve as a key tool in translational research.
VolitionRx (NYSE AMERICAN: VNRX) ha annunciato la sua prima vendita commerciale del metodo Ad Alta Capacità Sintetico per la Sepsi, una tecnologia innovativa che misura l'attivazione e l'inibizione delle Trappole Extracellulari dei Neutrofili (NETs) nel sangue intero in tempo reale. Questo approccio rivoluzionario aiuta le aziende a sviluppare nuovi terapeutici per la sepsi e le malattie correlate ai NETs.
La tecnologia affronta significative limitazioni nella ricerca precedente misurando direttamente i NETs nel sangue intero, evitando potenziali alterazioni nelle risposte dei neutrofili causate da procedure di isolamento. Il metodo fornisce un ambiente più pertinente dal punto di vista fisiologico per studiare le risposte dei neutrofili e consente una misurazione precisa della formazione dei NETs.
La sepsi, responsabile di circa 370.000 decessi negli Stati Uniti ogni anno, coinvolge i NETs che sono essenziali per intrappolare e neutralizzare i patogeni. Tuttavia, la loro sovrapproduzione può portare a danni ai tessuti e progressione della malattia. Questa nuova tecnologia mira a migliorare la comprensione delle condizioni caratterizzate da una formazione incontrollata dei NETs e a fungere da strumento chiave nella ricerca traslazionale.
VolitionRx (NYSE AMERICAN: VNRX) ha anunciado su primera venta comercial de su método Sintético de Sepsis de Alto Rendimiento, una tecnología innovadora que mide la activación e inhibición de las Trampas Extracelulares de Neutrófilos (NETs) en sangre completa en tiempo real. Este enfoque ayuda a las empresas a desarrollar nuevos tratamientos terapéuticos para la sepsis y enfermedades relacionadas con NETs.
La tecnología aborda limitaciones significativas en investigaciones previas al medir NETs directamente en sangre completa, evitando alteraciones potenciales en las respuestas de los neutrófilos causadas por procedimientos de aislamiento. El método proporciona un entorno más relevante desde el punto de vista fisiológico para estudiar las respuestas de los neutrófilos y permite una medición precisa de la formación de NETs.
La sepsis, responsable de aproximadamente 370,000 muertes anuales en EE. UU., implica NETs que son esenciales para atrapar y neutralizar patógenos. Sin embargo, su sobreproducción puede causar daño tisular y progresión de la enfermedad. Esta nueva tecnología tiene como objetivo mejorar la comprensión de las condiciones caracterizadas por la formación incontrolada de NETs y servir como una herramienta clave en la investigación traslacional.
VolitionRx (NYSE AMERICAN: VNRX)는 고처리량 합성 패혈증 방법의 첫 상업적 판매를 발표했습니다. 이 혁신적인 기술은 전체 혈액에서 화농백혈구 세포외 유격(NETs)의 활성화 및 억제를 실시간으로 측정합니다. 이 혁신적 접근법은 기업들이 패혈증 및 NETs 관련 질병을 위한 새로운 치료제를 개발하는 데 도움을 줍니다.
이 기술은 NETs를 전체 혈액에서 직접 측정함으로써 이전 연구에서의 주요 제한 사항을 해결하며, 분리 절차로 인한 화농백혈구 반응의 잠재적 변화를 피합니다. 이 방법은 화농백혈구 반응을 연구하는 데 생리적으로 더 관련성 높은 환경을 제공하고, NETs 형성을 정확하게 측정할 수 있게 합니다.
패혈증은 매년 약 370,000명의 미국 사망자를 초래하며, NETs는 병원체를 잡고 무력화하는 데 필수적입니다. 하지만 과도한 생산은 조직 손상 및 질병 진행을 초래할 수 있습니다. 이 새로운 기술은 통제되지 않는 NETs 형출에 의해 특징지어지는 상태를 이해하는 데 도움을 주고, 번역 연구에서 중요한 도구로 작용할 것입니다.
VolitionRx (NYSE AMERICAN: VNRX) a annoncé sa première vente commerciale de sa méthode de Sepsie Synthétique à Haut Débit, une technologie révolutionnaire qui mesure l'activation et l'inhibition des Pièges Extracellulaires de Neutrophiles (NETs) dans le sang total en temps réel. Cette approche innovante aide les entreprises à développer de nouveaux traitements thérapeutiques pour la sepsie et les maladies associées aux NETs.
La technologie répond à d'importantes limitations des recherches antérieures en mesurant directement les NETs dans le sang total, évitant ainsi des altérations potentielles des réponses neutrophiles causées par des procédures d'isolement. La méthode offre un environnement plus pertinent sur le plan physiologique pour étudier les réponses des neutrophiles et permet une mesure précise de la formation des NETs.
La sepsie, responsable d'environ 370 000 décès aux États-Unis chaque année, implique des NETs qui sont essentiels pour piéger et neutraliser les pathogènes. Cependant, leur surproduction peut entraîner des lésions tissulaires et la progression de la maladie. Cette nouvelle technologie vise à améliorer la compréhension des conditions caractérisées par une formation incontrôlée des NETs et à servir d'outil clé dans la recherche translationnelle.
VolitionRx (NYSE AMERICAN: VNRX) hat seinen ersten kommerziellen Verkauf der Hochdurchsatz-Synthese-Sepsis-Methode bekannt gegeben, einer bahnbrechenden Technologie, die die Aktivierung und Hemmung von Neutrophilen Extrazellulären Fallen (NETs) in Vollblut in Echtzeit misst. Dieser innovative Ansatz hilft Unternehmen, neue therapeutische Produkte gegen Sepsis und NETs-bezogene Krankheiten zu entwickeln.
Die Technologie adressiert erhebliche Einschränkungen der bisherigen Forschung, indem NETs direkt im Vollblut gemessen werden, wodurch mögliche Veränderungen der Neutrophilenantworten, die durch Isolationsverfahren verursacht werden, vermieden werden. Das Verfahren bietet eine physiologisch relevantere Umgebung zur Untersuchung der Neutrophilenantworten und ermöglicht eine präzise Messung der NETs-Bildung.
Sepsis, die jährlich etwa 370.000 Todesfälle in den USA verursacht, umfasst NETs, die entscheidend sind, um Krankheitserreger einzufangen und zu neutralisieren. Ihre Überproduktion kann jedoch zu Gewebeschäden und Krankheitsfortschreiten führen. Diese neue Technologie zielt darauf ab, das Verständnis von Bedingungen zu verbessern, die durch die unkontrollierte NETs-Bildung gekennzeichnet sind, und als zentrales Werkzeug in der Translation Forschung zu dienen.
- First commercial sale of High Throughput Synthetic Sepsis method
- Technology addresses major research limitations in NETs measurement
- Enables real-time monitoring of NETs in whole blood
- Potential for new therapeutic developments in sepsis treatment
- None.
Insights
This commercial breakthrough represents a strategic pivot for Volition, expanding beyond their traditional diagnostic focus into the lucrative drug development tools market. The timing is particularly significant as the global sepsis diagnostics market is projected to reach
The technology's key differentiator - studying NETs in whole blood rather than isolated neutrophils - addresses a critical limitation in current research methodologies. This approach could significantly reduce false positives and accelerate drug development timelines, potentially saving pharmaceutical companies millions in research costs. The high-throughput capability suggests scalability for large pharmaceutical studies, making it an attractive tool for drug discovery programs.
From a business perspective, this marks Volition's entry into the bio-partnering model, diversifying revenue streams beyond diagnostic development. The company's mention of active discussions with pharmaceutical companies suggests near-term commercialization opportunities. This could lead to multiple revenue streams through:
- Direct sales of the research platform
- Ongoing service contracts for drug development support
- Potential licensing agreements for the technology
- Future collaboration opportunities in biomarker development
However, success will depend on validation by pharmaceutical partners and the technology's ability to demonstrate clear advantages in drug development efficiency. The market's reception of this tool could indicate Volition's potential to monetize other aspects of their Nu.Q® platform technology.
Expanding commercial offering as a bio-partnering model, currently in active discussions with pharmaceutical companies
Dr. Jasmine Kway, CEO of Singapore Volition and Commercial Lead for Nu.Q® Discover said:
"Our High Throughput NETs model represents a critical breakthrough in understanding neutrophil biology; A fundamental understanding of NETs-related diseases in vivo has been challenging to date."
"Most studies rely on isolated primary neutrophils, which miss many potential crosstalk events which happen in whole blood. By enabling more precise measurement of NETs formation, we're opening new pathways for therapeutic interventions in NETs-related diseases."
Key Highlights of Rapid High-Throughput Model
- Method to quantitatively monitor NETs release in real time
- Eliminates neutrophil isolation steps that can alter cellular responses
- Builds on foundational research published in the Journal of Thrombosis and Hemostasis
- Provides a more physiologically relevant environment for studying neutrophil responses
Dr. Terry Kelly, Chief Innovation Officer at Volition America, added:
"This marks the culmination of the last two years of work demonstrating the ability to induce and inhibit NETs formation in healthy blood using an automated high throughput system. There is an increasing trend of published scientific literature about NETs as scientists and biopharmaceutical companies race to develop new interventions based on an improved understanding of the underlying biology and mechanisms at play."
Volition's innovative approach addresses a significant technical limitation in previous research. By measuring NETs directly in whole blood, the method avoids potential alterations in neutrophil responses caused by isolation procedures, as highlighted by recent commentary in JTH.
"This technology has the potential to unlock new understanding of conditions characterized by uncontrolled NETs formation and can serve as a key tool in translational research and the study of NETosis related disease."
Sepsis, NETs and NETosis
Sepsis is a life-threatening organ dysfunction caused by a dysregulated host response to infection It is responsible for ~370,000 US deaths annually. Neutrophils are an integral part of the innate immune response and rapidly clear pathogens from circulation using neutrophil extracellular traps (NETs) released through a process called NETosis.
NETs have become more relevant in disease but have not been widely characterized in humans. NETs are essential for trapping and neutralizing pathogens, but overproduction or uncontrolled formation (NETosis) can lead to tissue damage and disease progression during the inflammatory response.
Studies in NETosis have been mostly limited to isolated systems with unnatural stimulation. However, understanding natural NETosis activation and the underlying mechanisms could lead to new biomarkers and understanding of how these neutrophil associated diseases are regulated in vivo.
Volition is developing simple, easy-to-use, cost-effective blood tests to help diagnose and monitor a range of life-altering diseases in both humans and animals.
For more information about Volition's technology go to: www.volition.com
About Volition
Volition is a multi-national company focused on advancing the science of epigenetics. Volition is dedicated to saving lives and improving outcomes for people and animals with life-altering diseases through earlier detection, as well as disease and treatment monitoring.
Through its subsidiaries, Volition is developing and commercializing simple, easy to use, cost-effective blood tests to help diagnose and monitor a range of diseases, including some cancers and diseases associated with NETosis, such as sepsis. Early diagnosis and monitoring have the potential not only to prolong the life of patients but also improve their quality of life.
Volition's research and development activities are centered in
The contents found at Volition's website address are not incorporated by reference into this document and should not be considered part of this document. Such website address is included in this document as an inactive textual reference only.
Media Enquiries:
Louise Batchelor, Volition, mediarelations@volition.com, +44 (0)7557 774620
Investor Relations
Jeremy Feffer, LifeSci Advisors, jfeffer@lifesciadvisors.com, +1-212-915-2568
Safe Harbor Statement
Statements in this press release may be "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, that concern matters that involve risks and uncertainties that could cause actual results to differ materially from those anticipated or projected in the forward-looking statements. Words such as "expects," "anticipates," "intends," "plans," "aims," "targets," "believes," "seeks," "estimates," "optimizing," "potential," "goal," "suggests," "could," "would," "should," "may," "will" and similar expressions identify forward-looking statements. These forward-looking statements relate to, among other topics, Volition's expectations related to revenue opportunities and growth, the timing, completion, success and delivery of data from clinical studies, the timing of publications, , the effectiveness and availability of Volition's blood-based diagnostic, prognostic and disease monitoring tests, Volition's ability to develop and successfully commercialize such test platforms for early detection of cancer and other diseases as well as serving as a diagnostic, prognostic or disease monitoring tools for such diseases, and Volition's success in securing licensing and/or distribution agreements with third parties for its products. Volition's actual results may differ materially from those indicated in these forward-looking statements due to numerous risks and uncertainties, including, without limitation, results of studies testing the efficacy of its tests. For instance, if Volition fails to develop and commercialize diagnostic, prognostic or disease monitoring products, it may be unable to execute its plan of operations. Other risks and uncertainties include Volition's failure to obtain necessary regulatory clearances or approvals to distribute and market future products; a failure by the marketplace to accept the products in Volition's development pipeline or any other diagnostic, prognostic or disease monitoring products Volition might develop; Volition's failure to secure adequate intellectual property protection; Volition will face fierce competition and Volition's intended products may become obsolete due to the highly competitive nature of the diagnostics and disease monitoring market and its rapid technological change; downturns in domestic and foreign economies; and other risks, including those identified in Volition's most recent Annual Report on Form 10-K and Quarterly Reports on Form 10-Q, as well as other documents that Volition files with the Securities and Exchange Commission. These statements are based on current expectations, estimates and projections about Volition's business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Forward-looking statements are made as of the date of this press release, and, except as required by law, Volition does not undertake an obligation to update its forward-looking statements to reflect future events or circumstances.
Nucleosomics™, Capture-PCR™ and Nu.Q® and their respective logos are trademarks and/or service marks of VolitionRx Limited and its subsidiaries. All other trademarks, service marks and trade names referred to in this press release are the property of their respective owners.
View original content:https://www.prnewswire.com/news-releases/volition-signs-first-commercial-project-utilizing-rapid-high-throughput-model-in-the-study-of-netosis-302370192.html
SOURCE VolitionRx Limited
FAQ
What is the significance of VNRX's new High Throughput Synthetic Sepsis method?
How does VNRX's new NETs measurement technology differ from traditional methods?
What market opportunity does VNRX's NETs technology address?
What are the key features of VNRX's Rapid High-Throughput Model?
How could VNRX's NETs technology impact drug development?
